Xcytrin motexafin gadolinium: Phase III

PCYC reported data from 25 patients given Xcytrin followed by 10 days of radiation during the open-label lead-in stage of the company's 425-patient U.S. Phase III trial. Patients had an average of 12 brain metastases resulting from lung, breast or other cancers. MRI scans from 19 patients showed a 50 percent reduction in tumor volume in 13 patients, while 3 had tumor progression. Improvement or maintenance of neurocognitive function was seen in 19 of 25 patients, with the remaining 6 patients showing deterioration of function. Data were presented at the American Society for Therapeutic Radiology and Oncology meeting in San Antonio. ...